Quince Therapeuticsincis A Late Stage Biotechnology Company Based In South San Franciscocaliforniafounded In 2012 And Formerly Known As Cortexymeinc The Company Focuses On Developing And Commercializing Therapeutics For Rare And Debilitating Diseasesquince Leverages Its Aide Technology Platformwhich Automates The Encapsulation Of Therapeutics Into Patientsred Blood Cellsenhancing Drug Delivery Precision The Lead Product Candidateerydexis Designed To Treat Ataxia Telangiectasiaa T A Rare Pediatric Neurodegenerative Disorderthis Therapy Utilizes Autologous Red Blood Cells To Deliver Dexamethasone Sodium Phosphateaiming To Reduce Neurological Declineerydex Has Received Fast Track Designation From The U Sfdaindicating A Significant Unmet Medical Need In A T Treatmentquince Is Currently Conducting The Phase 3 Neat Trial To Evaluate The Safety And Efficacy Of Erydexwith Enrollment Expected To Conclude In Mid 2025
No conferences found for this company.
| Company Name | Erydel Spa |
| Country |
Italy
|
| Address | N/A |
| Telephone | N/A |
| N/A |
